BB Pureos Bioventures LP

https://www.pureosbio.com

Pureos Bioventures invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases *

	Start	2018-02-01 established (approx)
	Group	Bellevue (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Escher, Dominik (Belleveue 201001 Managing Partner at BB Pureos Bioventures before ESBATech CEO + Founder)
	Person 2	Breiner, Klaus (BB Biotech Ventures + Vaximm 201605 Executive Chairman)

	Region	Guernsey
	Country	United Kingdom (GB)
	Street	Trafalgar Square Les Banques
	City	GY1 3QL St. Peter Port, Guernsey
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	205,000,000 (capital under management (2021) 2021-09-21)

		* Document for »About Section«: Alentis Therapeutics AG. (4/13/23). "Press Release: Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1". Basel.

		Record changed: 2024-05-07

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Bellevue (Group)

[1] Pureos Partners AG. (1/17/23). "Press Release: Pureos Partners Welcomes Dr. Ulf Grawunder to Its Team as Venture Partner". Pfäffikon....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]